The addition of β-adrenergic antagonists to the treatment regimen for heart failure has validated the neurohormonal hypothesis and provided much-improved outcomes. This benefit had been in question ...

Although significant advances have been made in the pharmacologic and device-based treatment of HF, our understanding of the full range of the signaling and genomic mechanisms involved in HF ...

Please provide your email address to receive an email when new articles are posted on . CuraSen Therapeutics has announced positive data from a phase 2a study of its combination adrenergic activator, ...

ASTHMA can be defined as a disease of the bronchi producing diffuse, reversible bronchial obstruction. The bronchial tree of patients with asthma is hypersensitive to the effects of dust, cold air, ...

Researchers in Japan have discovered that the adrenergic nervous system controls when white blood cells circulate through the body, boosting the immune response by retaining T and B cells in lymph ...

Overuse of rescue medication among asthma patients is associated with increased exacerbations and higher total and asthma-related healthcare costs. Objective: To assess whether increased short-acting ...

Researchers have made a significant discovery about how the gut microbiome interacts with cells to cause cardiovascular disease. The study found phenylacetylglutamine (PAG), produced by gut bacteria ...

RAPIBLYK (R) is an ultra-short-acting, selective beta-1 adrenergic receptor blocker administered intravenously in a monitored hospital setting. Its pharmacological profile allows for rapid onset and ...